NCT00472030View on ClinicalTrials.gov

Efficacy and Safety of Omalizumab in Bullous Pemphigoid

PHASE4CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Bullous Pemphigoid
Interventions
DRUG

Omalizumab

Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.

DRUG

prednisone

Prednisone, to a maximum dose of 0.5 mg/kg/day.

Trial Locations (1)

52242

University of Iowa, Department of Dermatology, Iowa City

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Iowa

OTHER